Microbiota-Dependent Enterocyte Oxytocin Signaling Emerges as a Mechanistic Link in Autism Spectrum Disorder
核心洞察
Research on autism spectrum disorder (搜索) increasingly focuses on early-life microbiota composition, supporting the development of microbiota-based diagnostic and therapeutic approaches.
Alterations in microbial diversity may influence key neurodevelopmental processes, including microglial and immune activation, metabolite balance, and synaptic pruning in the developing brain.
The gut microbiome has been implicated in multiple neurodevelopmental and psychiatric conditions beyond ASD, including depression (搜索), schizophrenia (搜索), bipolar disorder (搜索), ADHD, and neurodegenerative diseases such as Parkinson's and Alzheimer's disease (搜索).
Research on Autism Spectrum Disorder (搜索) (ASD) has increasingly focused on early-life microbiota composition, supporting the development of microbiota-based diagnostic and therapeutic approaches. Alterations in microbial diversity and composition may influence key neurodevelopmental processes, including microglial and immune activation, metabolite balance, and synaptic pruning in the developing brain.
The Challenge of Identifying an ASD-Specific Microbial Signature
However, microbiota alteration is not unique to ASD. The gut microbiome has been implicated in several neurodevelopmental and psychiatric conditions, including depression (搜索), schizophrenia (搜索), bipolar disorder (搜索), attention-deficit/hyperactivity disorder (搜索), and neurodegenerative diseases such as Parkinson's and Alzheimer's disease (搜索). Given the frequent clinical and medical comorbidities associated with ASD, identifying a distinct microbial profile, if any, that is unique to ASD remains particularly challenging. Future progress may therefore rely on clarifying the cellular and molecular pathways through which microbial signals influence specific neurodevelopment and behavioral phenotypes.
A Persistent Translational Gap
The rapid rise of microbiome-based explanations for ASD has highlighted a persistent translational gap: causal claims have advanced faster than the evidence supporting them. Human studies remain highly susceptible to confounding, and intervention trials are frequently limited by small sample sizes, inadequate controls, and heterogeneous outcomes.
Recent perspectives identify the same recurring methodological weaknesses across observational cohorts, animal models, and clinical trials, including underpowered study designs, insufficient control of confounds, and fragile statistical inference. Systematic reviews of microbiome-targeted interventions in ASD, including probiotics, prebiotics and fecal microbiota transplantation, reinforce this concern by documenting substantial methodological and outcome heterogeneity.
Implications for the Field
At the same time, public and commercial enthusiasm surrounding "psychobiotics" has advanced faster than the underlying evidence base. This underscores the need for rigorous, mechanistically grounded research to bridge the gap between promising preclinical observations and clinically validated interventions for ASD.